Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130

H. S. Rugo, Leisha A. Emens(Sidney Kimmel Cancer Center), Hiroji Iwata(Aichi Cancer Center), Sherene Loi(The University of Melbourne), Sylvia Adams(NYU Langone Health), Mark Kockx(HistoGeneX (Belgium)), Luciana Molinero, Peter Schmid(Inserm), Giulia Viale(Vita-Salute San Raffaele University), Andreas Schneeweiß(Heidelberg University), Jane Yuet Ching Hui, Anh Nguyen Duc(Roche (Switzerland)), EP Winer, V. Diéras, Dieter Peeters(GZA Ziekenhuizen Campus Sint-Augustinus), C.H. Barrios, J. Lin
Annals of Oncology
October 1, 2019
10.1093/annonc/mdz394.009
Cited by 115

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k